Virtual Myeloma Community Workshop: What's Next? - Managing Myeloma at Relapse (https://www.myeloma.org/videos/imf-virtual-mcw-whats-next-managing-myeloma-relapse-2026)
DOWNLOAD SLIDES (https://isu.pub/TSGfG51)
Learn how to navigate relapsed multiple myeloma with three of the world's leading myeloma specialists — covering CAR T cell therapy, bispecific antibodies, antibody drug conjugates, supportive care, and the future treatment pipeline.
🔬 WHAT'S COVERED IN THIS WORKSHOP:
Dr. Joseph Mikhael (IMF Medical Advisor) opens with the biology of relapse and 10 essential principles every patient should know — including a newly FDA-approved drug announced just weeks before this webinar.
Dr. Luciano Costa (University of Alabama at Birmingham) breaks down CAR T cell therapy: how it works, what to expect from leukapheresis and manufacturing, approved therapies (ide-cel and cilta-cel), clinical trial results, side effects, and emerging next-generation approaches including in vivo and allogeneic CAR T.
Dr. Shonali Midha (Dana-Farber Cancer Institute) covers off-the-shelf immunotherapies: bispecific antibodies (teclistamab, elranatamab, linvoseltamab, talquetamab) and antibody drug conjugates (belantamab mafodotin) — how they work, response rates, combination strategies, and how to sequence them with CAR T.
Patricia Mangan, RN, MSN, APRN-BC (University of Pennsylvania) leads a practical deep dive into supportive care: managing cytokine release syndrome (CRS), ICANS, infections, GPRC5D-related skin and taste toxicities, fatigue, and shared decision-making.
Dr. Mikhael closes with a look at what's coming next: trispecific antibodies, in vivo CAR T, allogeneic CAR T, CELMoDs, and more.
Workshop chapters Topics Covered in This Workshop
Dr. Mikhael explained the biology of myeloma progression: patients move from precursor conditions (MGUS or smoldering myeloma) to active myeloma requiring treatment, achieve deep responses, but experience relapse through clonal evolution — the disease mutates and develops resistance. While over 95% of newly diagnosed patients respond to first-line therapy, residual disease and immune surveillance failure eventually allow regrowth.
Dr. Luciano Costa presented a comprehensive overview of CAR T (chimeric antigen receptor T cell) therapy.
Dr. Shonali Midha presented the two major classes of off-the-shelf T cell-engaging therapies available for relapsed myeloma.
Patricia Mangan, RN, MSN, APRN-BC presented a comprehensive overview of supportive care for patients with relapsed myeloma receiving immunotherapy.
What is Relapse and How do we Deal with it?
Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO
IMF Medical Advisor
(TGen, City of Hope—Phoenix, AZ)
What are the Key Treatments we have for Relapsed Myeloma?
Shonali Midha, MD
Dana-Farber Cancer Institute—Boston, MA)
CAR-T Cell Therapy: What it is and How we deliver it
Luciano Costa, MD
University of Alabama Medicine, The Kirklin Clinic, Birmingham, AL
Myeloma: Putting the Pieces of the Puzzle Together
Patricia Mangan, RN, MSN, APRN-BC
IMF Nurse Leadership Board Member
(University of Pennsylvania, Abramson Cancer Center — Philadelphia, PA )
Faculty Roundtable: The Importance of Clinical Trials
Q&A with Panel
Closing Remarks
Additional Resources:
Download the IMF's Multiple Myeloma Informational Booklets:
Download IMF publications (https://www.myeloma.org/cancer-information-series)
What Is a Clinical Trial? (https://www.myeloma.org/clinical-trials)
*Of note, Venetoclax has already been approved to treat acute myeloid leukemia, chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults and is now being evaluated to treat other types of cancers, including multiple myeloma. It is part of a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors that work by blocking the action of BCL-2 (a protein in the body that regulates cell death). Trials using Venetoclax were discussed in this webinar. You can learn about these three trials at the following links:
- CANOVA Clinical Trial Fact Sheet (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2021-08/CTFS_Venetoclax%20CANOVA_M13-494_NCT03539744_a3.pdf)
clinicaltrials.gov Identifier: NCT03539744 - Phase II Relapsed or Refractory Venetoclax Trial (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2021-08/CTFS_Venetoclax_M15-338_NCT02899052_a3.pdf)
clinicaltrials.gov Identifier: NCT02899052 - Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib (https://imf-d8-prod.s3.us-west-1.wasabisys.com/2021-08/CTFS_Venetoclax_M15-654_NCT03314181_a3.pdf)
clinicaltrials.gov Identifier: NCT03314181
Workshop Sponsors:
With Support From: Abbvie, Amgen, BMS, GSK, Johnson & Johnson, Johnson & Johnson w Legend, Karyopharm, Kite, and Pfizer
(The IMF is not responsible for content provided by the links below and you may be subject to the Privacy Policy and Terms & Conditions of the destination site(s).)
.png)
